Humacyte Inc (HUMA)

$1.32 +0.13 (10.92%)
Market Cap 184.59M
Revenue (ttm) 0.00
Net Income (ttm) -148.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 4,442,400
Avg Vol 4,082,770
Day's Range N/A - N/A
Shares Out 155.12M
Stochastic %K 3%
Beta 1.64
Analysts Strong Sell
Price Target $11.43

Latest News on HUMA

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

May 9, 2025, 8:00 AM EDT - 3 days ago

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Mar 28, 2025, 1:48 PM EDT - 6 weeks ago

Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call Transcript

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Mar 28, 2025, 7:30 AM EDT - 6 weeks ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Mar 26, 2025, 8:00 AM EDT - 6 weeks ago

Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Mar 25, 2025, 8:35 PM EDT - 6 weeks ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Mar 25, 2025, 4:01 PM EDT - 6 weeks ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Mar 10, 2025, 8:00 AM EDT - 2 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

Trestle Bio Announces Research Collaboration with Humacyte

Mar 6, 2025, 8:00 AM EST - 2 months ago

Trestle Bio Announces Research Collaboration with Humacyte

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Mar 3, 2025, 8:00 AM EST - 2 months ago

Humacyte to Host In-Person and Virtual Investor Event in New York to Discuss Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma on March 6, 2025

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 2 months ago

Humacyte to Present at the TD Cowen 45th Annual Health Care Conference

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Feb 27, 2025, 8:00 AM EST - 2 months ago

Humacyte Announces Issuance of U.S. Patent Covering Manufacturing of Symvess™ and Other Bioengineered Tissues

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Feb 26, 2025, 8:00 AM EST - 2 months ago

Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Feb 20, 2025, 1:35 PM EST - 2 months ago

Humacyte, Inc. - Investors of Humacyte Stock Encouraged to Contact Kehoe Law Firm, P.C. - HUMA

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

Jan 21, 2025, 8:00 AM EST - 3 months ago

Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Jan 17, 2025, 10:30 AM EST - 4 months ago

HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

Jan 9, 2025, 5:45 AM EST - 4 months ago

Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Jan 2, 2025, 8:15 AM EST - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte

Humacyte Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm

Dec 21, 2024, 12:15 PM EST - 5 months ago

Humacyte Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm

Humacyte stock may fail to sustain today's gains: find out more

Dec 20, 2024, 12:35 PM EST - 5 months ago

Humacyte stock may fail to sustain today's gains: find out more